Improved Real-Time PCR Assay for Homogeneous Multiplex Genotyping of Four CYP2C9 Alleles with Hybridization Probes

Clinical Chemistry

Volumn 49, Issue 12, 2003, Pages 2109-2111

  Yip, Shea Ping ^a   Lee, Sau Yin ^a   To, Shing Shun T ^a   Wong, Maria L ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; CYSTEINE; CYTOCHROME P450 2C9; DYE; GLUTAMIC ACID; ISOLEUCINE; LEUCINE; PHENYTOIN; PROTEIN; THREONINE; WARFARIN;

ALLELE; AMINO ACID SUBSTITUTION; ASSAY; CAUCASIAN; CHINESE; DNA POLYMORPHISM; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC CODE; GENOTYPE; HUMAN; HYBRIDIZATION; LETTER; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; RESTRICTION MAPPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION;

EID: 0344514834     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023622     Document Type: Letter

References (6)

1. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
2. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54: 1257-70.
3. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. Clin Chim Acta 2001;308:9-15.
4. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-9.
5. Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants . and CYP2C9 allelic variant in a German population. Br J Clin Pharmacol 2002;54:518-21.
6. Borlak J, Thum T. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clin Chem 2002;48:1592-4.